DNA methylation of GSTP1 in human prostate tissues: Pyrosequencing analysis

Korean Journal of Urology

Volumn 53, Issue 3, 2012, Pages 200-205

  Yoon, Hyung Yoon ^a   Kim, Young Won ^a   Kang, Ho Won ^a   Kim, Won Tae ^a   Yun, Seok Joong ^a   Lee, Sang Cheol ^a   Kim, Wun Jae ^a   Kim, Yong June ^a  

^a Chungbuk National University College of Medicine   (South Korea)

Author keywords

GSTP1; Methylation; Neoplasms; Prostate

Indexed keywords

GLUTATHIONE TRANSFERASE P1; PROSTATE ANTIGEN;

ARTICLE; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA METHYLATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION;

EID: 84930486268     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2012.53.3.200     Document Type: Article

References (18)

1. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2009;182:2232-41.
2. Schröder F, Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. Eur Urol 2008;54:274-90.
3. Kim HW, Ko YH, Kang SH, Lee JG. Predictive factors for prostate cancer in biopsy of patients with prostate-specific antigen levels equal to or less than 4 ng/ml. Korean J Urol 2011;52:166-71.
4. Seo HS, Lee NK. Predictors of PSA screening among men over 40 years of age who had ever heard about PSA. Korean J Urol 2010; 51:391-7.
5. Yang JB, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM. Outcome of prostate biopsy in men younger than 40 years of age with high prostate-specific antigen (PSA) levels. Korean J Urol 2010;51:21-4.
6. van Vlodrop IJ, Niessen HE, Derks S, Baldewijns MM, Van Criekinge W, Herman JG, et al. Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin Cancer Res 2011;17:4225-31.
7. Hoque MO. DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev Mol Diagn 2009;9:243-57.
8. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005;5:223-31.
9. Kim WJ, Kim YJ. Epigenetic biomarkers in urothelial bladder cancer. Expert Rev Mol Diagn 2009;9:259-69.
10. Kim YJ, Yoon HY, Kim SK, Kim YW, Kim EJ, Kim IY, et al. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling. Clin Cancer Res 2011;17:4523-30.
11. Marsh S. Pyrosequencing applications. Methods Mol Biol 2007;373:15-24.
12. Vasiljevic NA, Wu K, Brentnall AR, Kim DC, Thorat MA, Kudahetti SC, et al. Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. Dis markers 2011;30:151-61.
13. Phe V, Cussenot O, Roupret M. Methylated genes as potential biomarkers in prostate cancer. BJU Int 2010;105:1364-70.
14. Hopkins TG, Burns PA, Routledge MN. DNA methylation of GSTP1 as biomarker in diagnosis of prostate cancer. Urology 2007;69:11-6.
15. Gonzalgo ML, Nakayama M, Lee SM, De Marzo AM, Nelson WG. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. Urology 2004;63:414-8.
16. Alumkal JJ, Zhang Z, Humphreys EB, Bennett C, Mangold LA, Carducci MA, et al. Effect of DNA methylation on identification of aggressive prostate cancer. Urology 2008;72:1234-9.
17. Ellinger J, Bastian PJ, Jurgan T, Biermann K, Kahl P, Heukamp LC, et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology 2008;71: 161-7.
18. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004;64:1975-86.